Aspira Women's Health (AWHL)
OTHER OTC:AWHL
Top Page
Aspira Women's Health
(OTC:AWHL)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.46
▼(-9.00% Downside)
Action:ReiteratedDate:12/31/25
The score is held down primarily by weak financial health (negative equity, ongoing losses, and negative operating cash flow). Technicals are comparatively stronger with an established uptrend, but overbought signals temper the setup. Corporate events are broadly positive yet partly offset by dilution risk, while valuation remains constrained by unprofitability and no dividend.
Positive Factors
AI-powered multi-omic platform
Aspira's OvaSuite AI, multi-omic strategy targets a large, clearly defined addressable market across ovarian risk, adnexal mass triage and endometriosis. If clinical performance and adoption persist, the platform creates durable product differentiation and expansion opportunities across multiple pelvic disease states.
Negative Factors
Negative shareholders' equity
Negative stockholders' equity is a structural solvency signal: liabilities exceed assets. This limits financial flexibility, raises creditor risk and can constrain strategic options like M&A or large commercial investments unless equity is restored, pressuring long-term capital stability if not remedied.
Read all positive and negative factors
Positive Factors
Negative Factors
AI-powered multi-omic platform
Aspira's OvaSuite AI, multi-omic strategy targets a large, clearly defined addressable market across ovarian risk, adnexal mass triage and endometriosis. If clinical performance and adoption persist, the platform creates durable product differentiation and expansion opportunities across multiple pelvic disease states.
Read all positive factors
Aspira Women's Health (AWHL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.21M
Dividend YieldN/A
Average Volume (3M)100.39K
Price to Earnings (P/E)―
Beta (1Y)1.97
Revenue Growth4.17%
EPS Growth68.47%
CountryUS
Employees66
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,480,410
10 Day Avg. Volume120,018
30 Day Avg. Volume100,391
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$32.66M
Aspira Women's Health Business Overview & Revenue Model
Company Description
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignanc...
How the Company Makes Money
Aspira Women's Health generates revenue primarily through the sale of its diagnostic tests, such as OVA1 and Overa, to healthcare providers, hospitals, and laboratories. The company operates on a fee-for-service model, where they charge for each t...
Aspira Women's Health Earnings Call Summary
Earnings Call Date:Nov 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted growth in test volumes and significant achievements such as the New York State approval for OvaWatch and a major federal award for ENDOinform development. However, challenges such as severe weather impacting growth, increased expenses, and decreased cash reserves were noted. Despite these issues, the call emphasized strategic initiatives and improvements in margins, portraying a cautiously optimistic outlook.Positive Updates
Increase in OvaSuite Test Volume
Delivered over 6,000 OvaSuite tests in Q3 2024, a 4% increase compared to the same period in 2023.
Negative Updates
Impact of Severe Weather on Growth
Growth in test volume was negatively impacted by severe weather, including Hurricane Helene, affecting major markets.
Read all updates
Q3-2024 Updates
Positive
Negative
Increase in OvaSuite Test Volume
Delivered over 6,000 OvaSuite tests in Q3 2024, a 4% increase compared to the same period in 2023.
Read all positive updates
Company Guidance
During the third quarter of 2024, Aspira Women's Health Incorporated experienced a 4% growth in OvaSuite tests, delivering over 6,000 tests compared to approximately 5,783 in the same period in 2023. Despite severe weather, including Hurricane Helene, impacting key markets, the number of tests per sales representative rose by 21% over the first nine months of 2024 compared to 2023. The OvaSuite revenue increased by 2% to $2.3 million, with an average unit price of $376, slightly lower than the previous year's $383. Gross margins improved to 60%, and the company reported a reduction in cash used in operating activities by 12%, totaling $2.9 million for the quarter. Aspira also secured a $10 million federal award for the development of ENDOinform, enhancing its standing in the diagnostic market, while expanding its commercial reach, notably through a partnership with BioReference labs for OvaWatch distribution.Aspira Women's Health Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Aspira Women's Health Technical Analysis
Positive
0.50
Price Trends
0.38
Negative
0.43
Negative
0.39
Negative
Market Momentum
-0.01
Negative
50.67
Neutral
62.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AWHL, the sentiment is Positive. The current price of 0.5 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.38, and above the 200-day MA of 0.39, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.67 is Neutral, neither overbought nor oversold. The STOCH value of 62.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AWHL.
Aspira Women's Health Risk Analysis
Aspira Women's Health disclosed 37 risk factors in its most recent earnings report. Aspira Women's Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aspira Women's Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $45.50M | -92.19 | -10.07% | ― | 30.95% | 59.67% | |
56 Neutral | $140.09M | -1.46 | -302.55% | ― | 22.29% | 31.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $15.21M | -0.92 | ― | ― | 4.17% | 68.47% | |
47 Neutral | $26.65M | -3.41 | 76.82% | ― | 14.48% | 36.83% | |
46 Neutral | $11.20M | -0.95 | 80.66% | ― | -4.35% | -6.31% |
* Healthcare Sector Average
AWHL
Aspira Women's Health
0.35
0.24
232.38%
TRIB
Trinity Biotech
0.60
-0.04
-6.24%
VNRX
VolitionRX
0.20
-0.35
-64.36%
PRPO
Precipio
25.97
19.70
314.19%
BDSX
Biodesix
14.21
0.81
6.04%
Aspira Women's Health Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Aspira Women’s Health Secures New Subordinated Term Loan
Neutral
Jan 30, 2026
On January 30, 2026, Aspira Women’s Health Inc. entered into a Subordinated Business Loan and Security Agreement with Agile Lending, LLC as lead lender and Agile Capital Funding, LLC as collateral agent, under which the lenders provided a $1...
Business Operations and StrategyProduct-Related Announcements
Aspira Women’s Health Showcases AI Ovarian Diagnostics Platform
Positive
Dec 31, 2025
On December 29, 2025, Aspira Women’s Health published a new investor presentation outlining how its AI-powered, multi-omic diagnostic platform targets a more than 10.5 million–patient addressable market across ovarian cancer risk asses...
Private Placements and Financing
Aspira Women’s Health secures flexible equity financing agreement
Positive
Dec 23, 2025
On December 23, 2025, Aspira Women’s Health Inc. entered into a purchase agreement with institutional investor Lincoln Park Capital Fund, LLC that allows the company, at its discretion, to sell up to $10 million of its common stock over a 24...
Business Operations and StrategyProduct-Related Announcements
Aspira Women’s Health Expands Reach via Mayo Clinic Partnership
Positive
Dec 22, 2025
On December 16, 2025, Aspira Women’s Health entered into a five-year Laboratory Services Agreement with Mayo Collaborative Services, doing business as Mayo Clinic Laboratories, under which Aspira will supply its Ova1Plus and OvaWatch tests t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.